Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00192140 · ClinicalTrials.gov registry record · Phase 4
Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age
A Phase 4 study of Influenza, sponsored by MedImmune.
- Completed
- Registry status
- Phase 4
- Development phase
- 345
- Enrollment target
- 11
- Study locations
NCT00192140 is a Phase 4 study of Influenza that has completed, run by MedImmune. The registered enrollment target is 345 participants, below the 36,802-participant average among 156 other Influenza trials with a reported enrollment target (99% lower). The trial reports 11 study locations across 11 states.
The verdict
NCT00192140, a Phase 4 study of Influenza, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 345 participants
- Enrollment target
- 11
- Study locations
Study Summary
* To describe the proportion of individuals 5-49 years of age who shed vaccine strain viruses. * To describe the duration of shedding of vaccine viruses in individuals 5-49 years of age. * To describe the genotypic and phenotypic stability of shed vaccine viruses. * To describe the immune responses of FluMist in individuals 5-49 years of age. * To describe the safety of FluMist in individuals 5-49 years of age in relation to shedding and the immune response
Conditions Studied
Interventions
- BIOLOGICAL FluMist
Study Locations (11)
Florida
- SFBC International, Inc - Miami
Illinois
- Children's Memorial Hospital - Chicago
Kentucky
- Kentucky Pediatric / Adult Research, Inc - Bardstown
Maryland
- University of Maryland, School of Medicine - Baltimore
Missouri
- Center for Vaccine Development - St Louis
Nebraska
- Creighton University Medical Center - Omaha
Ohio
- Pediatric Clinical Trials International - Columbus
Pennsylvania
- Primary Physician's Research Inc. - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 345 participants |
| Start Date | 2004-06 |
| Est. Completion | 2005-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00192140
The ClinicalTrials.gov registry entry for NCT00192140 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 345 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,802-participant average among 156 other Influenza trials with a reported enrollment target (99% lower). The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 1 intervention - of which FluMist is the first listed.
NCT00192140 reports 11 study locations spanning 11 distinct geographic areas - top geographies include Florida, Illinois, Kentucky.
Frequently Asked Questions
What is clinical trial NCT00192140 about?
NCT00192140 is a clinical study titled "Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age". * To describe the proportion of individuals 5-49 years of age who shed vaccine strain viruses. * To describe the duration of shedding of vaccine viruses in individuals 5-49 years of age. * To describe the genotypic and phenotypic stability of shed vaccine viruses. * To describe the immune responses ...
What is the current status of trial NCT00192140?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 345 participants. The study started on 2004-06. Estimated completion is 2005-01.
What conditions does trial NCT00192140 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT00192140?
The interventions under investigation include: FluMist (BIOLOGICAL).
Who is sponsoring clinical trial NCT00192140?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00192140 being conducted?
This trial has 11 study locations across Florida, Illinois, Kentucky, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults
RECRUITING · Phase 4
-
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
RECRUITING · Phase 4
-
Bone Marrow and Peripheral Blood Immune Responses Study
RECRUITING · Phase 4
-
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine
COMPLETED · Phase 4
-
A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age
COMPLETED · Phase 4
-
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.